Stock price when the opinion was issued
The more successful of the GLP-1 stocks compared to NVO. Decent entry point. Trades in the 30s on forward PE, so there's a strong expectation of prescription growth; every reason to believe that's going to happen.
Be cautious on position size; don't be aggressive. Stock was down 10% yesterday because NVO made a deal with CVS to become its prime recommended product for obesity. So NVO is starting to compete more on price.
Company has a corner on the weight loss franchise, but this advantage wont last forever. Valuation very high - too high to buy right now (~50x earnings). Strong brand, and R&D department, but valuation too high. Better options in the market right now.